Articoli con mandati relativi all'accesso pubblico - Delvys Rodríguez-AbreuUlteriori informazioni
Non disponibili pubblicamente: 5
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
Mandati: Government of Spain
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
Mandati: European Commission, Government of Spain
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
M Barquín, V Calvo, F García-García, B Nuñez, E Sánchez-Herrero, ...
Cancer Epidemiology 67, 101737, 2020
Mandati: European Commission, Government of Spain
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
J Remon, E Nadal, M Dómine, J Ruffinelli, Y García, JC Pardo, R López, ...
Lung Cancer 147, 83-90, 2020
Mandati: US National Institutes of Health, Government of Spain
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
D Rodríguez-Abreu, M Cobo, S García-Román, S Viteri-Ramírez, ...
Lung Cancer 164, 8-13, 2022
Mandati: Government of Spain
Disponibili pubblicamente: 42
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
Mandati: US National Institutes of Health
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study
CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ...
Journal of Clinical Oncology 38 (21), 2369-2379, 2020
Mandati: US National Institutes of Health
Perioperative pembrolizumab for early-stage non–small-cell lung cancer
H Wakelee, M Liberman, T Kato, M Tsuboi, SH Lee, S Gao, KN Chen, ...
New England Journal of Medicine 389 (6), 491-503, 2023
Mandati: US National Institutes of Health
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ...
Therapeutic advances in medical oncology 10, 1758834017749748, 2018
Mandati: Banking Foundation "la Caixa"
Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial)
M Provencio, R Serna-Blasco, E Nadal, A Insa, MR García-Campelo, ...
Journal of Clinical Oncology 40 (25), 2924-2933, 2022
Mandati: European Commission, Government of Spain
Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer
M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ...
New England Journal of Medicine 389 (6), 504-513, 2023
Mandati: European Commission, Government of Spain
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized …
H Borghaei, CJ Langer, L Paz‐Ares, D Rodríguez‐Abreu, B Halmos, ...
Cancer 126 (22), 4867-4877, 2020
Mandati: US National Institutes of Health
Modulation of oxidative stress by ozone therapy in the prevention and treatment of chemotherapy-induced toxicity: review and prospects
B Clavo, F Rodríguez-Esparragón, D Rodríguez-Abreu, ...
Antioxidants 8 (12), 588, 2019
Mandati: Government of Spain
Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and …
E Conde, A Suarez-Gauthier, A Benito, P Garrido, R García-Campelo, ...
PLoS One 9 (9), e107200, 2014
Mandati: Government of Spain
Assessment of a new ROS1 immunohistochemistry clone (SP384) for the identification of ROS1 rearrangements in patients with non–small cell lung carcinoma: the ROSING study
E Conde, S Hernandez, R Martinez, B Angulo, J De Castro, ...
Journal of Thoracic Oncology 14 (12), 2120-2132, 2019
Mandati: Government of Spain
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
J González-Rincón, M Méndez, S Gómez, JF García, P Martín, C Bellas, ...
PLoS One 14 (2), e0212813, 2019
Mandati: Government of Spain
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
R Laza‐Briviesca, A Cruz‐Bermúdez, E Nadal, A Insa, ...
Clinical and Translational Medicine 11 (7), e491, 2021
Mandati: European Commission, Government of Spain
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
M Casarrubios, A Cruz-Bermúdez, E Nadal, A Insa, MR García Campelo, ...
Clinical Cancer Research 27 (21), 5878-5890, 2021
Mandati: European Commission, Government of Spain
Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non–small-cell lung cancer with untreated brain metastases (Atezo …
E Nadal, D Rodríguez-Abreu, M Simó, B Massutí, O Juan, G Huidobro, ...
Journal of Clinical Oncology 41 (28), 4478-4485, 2023
Mandati: Government of Spain
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
F Franco, E Carcereny, M Guirado, AL Ortega, R López-Castro, ...
PLoS One 16 (6), e0251761, 2021
Mandati: European Commission
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software